Elicit: Mechanism of Adalimumab in TNF-alpha Inhibition
TNF-alpha adalimumab mechanism
Adalimumab neutralizes TNF-alpha through high-affinity binding that blocks receptor interaction, while simultaneously inducing apoptosis in transmembrane TNF-alpha-expressing cells via complement-dependent and caspase-mediated mechanisms and modulating intracellular inflammatory pathways including NF-κB signaling and microRNA networks.
Abstract
Adalimumab functions through five complementary mechanisms to inhibit TNF-alpha activity. Structurally, adalimumab binds TNF-alpha with high affinity (KD 7.05-10 × 10⁻¹¹ M) through a large epitope (2,540 Ų buried surface area) that directly occupies the TNF receptor-binding site, blocking both soluble and transmembrane TNF-alpha. Beyond neutralization, adalimumab induces cytotoxic effects including complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and caspase-3-mediated apoptosis in transmembrane TNF-alpha-expressing cells. Adalimumab modulates intracellular signaling by reversing NF-κB pathway activation and downregulating genes including IKBKB, IRAK1, TRAF2, and MAP3K7, while simultaneously regulating anti-inflammatory microRNAs (miR-1297, miR-30a, miR-126-3p) and pro-inflammatory microRNAs (miR-146a-5p). Cell-type-specific effects include restoration of intracellular TNF-alpha levels in monocytes, CD36 upregulation through NADPH oxidase-mediated redox signaling, suppression of endothelial adhesion molecules, and TNF-RI blockade in osteoclasts.
Compared to other anti-TNF agents, adalimumab demonstrates a larger antigen-antibody interface than infliximab and unique complex-forming capacity unlike the receptor fusion protein etanercept. Adalimumab and infliximab both induce outside-to-inside reverse signaling and cell cycle arrest, mechanisms absent with etanercept that may explain their superior efficacy in Crohn’s disease and Wegener’s granulomatosis. Clinical applications are supported by biomarker potential (intracellular TNF-alpha levels, NF-κB-associated microRNAs), though neutralizing anti-adalimumab antibodies represent a resistance mechanism. The temporal hierarchy shows immediate binding effects, gene expression changes within 2-8 hours, and phenotypic restoration over months, indicating acute anti-inflammatory activity transitions to sustained cellular reprogramming.
Methods
We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question.
Screening
We screened in sources based on their abstracts that met these criteria:
- Mechanistic Focus: Investigates adalimumab’s mechanism of action in TNF-alpha inhibition OR examines adalimumab’s effects on TNF-alpha pathways.
- Mechanistic Measurements: Measures biomarkers, inflammatory mediators, cellular responses related to TNF-alpha inhibition.
- Study Design: Includes in vitro studies, animal models, human studies, or systematic reviews/meta-analyses.
- Adalimumab Population: Involves patients treated with adalimumab or focuses on adalimumab’s mechanism of action.
- Mechanistic Investigation: Includes mechanistic insights beyond reporting clinical efficacy or safety outcomes.
- Publication Type: Includes peer-reviewed articles or systematic reviews (excluding abstracts, editorials, opinions).
Results
Characteristics of Included Studies
| Study | Full Text Retrieved? | Experimental Model | Mechanism Category | Disease Context |
|---|---|---|---|---|
| Aleksandra Plata-Babula et al., 2025 | Yes | HaCaT keratinocytes (in vitro) | Binding/neutralization, Cellular regulation | Psoriasis |
| Shi Hu et al., 2013 | Yes | Crystal structure, E. coli, and CHO cells (in vitro) | Binding/neutralization (epitope binding, receptor blockade) | TNF-alpha-associated diseases |
| Carlos Zamora-Atenza et al., 2014 | Yes | Primary monocytes from RA patients (in vitro) | Binding/neutralization, Cytotoxic effects, Signal transduction, Cellular regulation, Tissue/organ effects | Rheumatoid arthritis |
| Raghav Oberoi et al., 2016 | Yes | THP-1 macrophages, HUVECs, hypercholesterolemic mice (in vitro and in vivo) | Binding/neutralization, Tissue/organ effects | Atherosclerosis, RA |
| H. Mitoma et al., 2008 | No | Jurkat T cells (in vitro) | Binding/neutralization, Cytotoxic effects, Signal transduction | RA and inflammatory disorders |
| J. Boyer et al., 2007 | Yes | Primary human monocytes (in vitro) | Signal transduction, Binding/neutralization | Chronic inflammatory diseases, RA |
| Shi Hu et al., 2014 | Yes | Structural studies (crystallography) | Binding/neutralization (epitope binding, receptor blockade) | TNF-alpha-associated diseases |
| Chong Shen et al., 2006 | No | THP-1 cells, SCID-Beige mice (in vitro and in vivo) | Binding/neutralization, Cytotoxic effects | Crohn’s disease, RA |
| B. Harvey & Z. Kaymakcalan, 2014 | No | Primary human osteoclast precursors (in vitro) | Binding/neutralization (receptor blockade) | TNF-alpha-related conditions |
| F. Prattichizzo et al., 2016 | Yes | HUVECs, MCF-7 cells, CACs from psoriasis patients (in vitro and human) | Binding/neutralization, Cellular regulation, Tissue/organ effects | Psoriasis, endothelial senescence |
Thematic Analysis of Adalimumab Mechanisms
Molecular Binding and TNF-Alpha Sequestration
Structural studies revealed the precise molecular basis of adalimumab’s interaction with TNF-alpha. Adalimumab binds through a large, highly complementary interface with a buried surface area of 2,540 Ų. The affinity of adalimumab for TNF-alpha is high, with KD values ranging from 7.05 × 10⁻¹¹ M to 1.0 × 10⁻¹⁰ M. The formation of adalimumab-TNF complexes appears critical to its function, with experiments demonstrating that complex formation enhances inhibitory effects two-fold.
Cytotoxic Mechanisms
Adalimumab induces apoptosis in transmembrane TNF-alpha-expressing cells through multiple pathways. Specifically, caspase-3 activation was demonstrated following adalimumab treatment, and this apoptotic effect could be abrogated by pan-caspase inhibitors in vivo. Adalimumab also induced cell cycle arrest in transmembrane TNF-alpha-expressing cells, reflecting outside-to-inside signal transduction through transmembrane TNF-alpha.
Signal Transduction and Pathway Modulation
NF-κB Pathway Regulation
In keratinocytes stimulated with lipopolysaccharide, adalimumab reversed the upregulation of multiple NF-κB-associated genes, with concordant changes at the protein level.
MicroRNA Modulation
Adalimumab regulated multiple microRNAs with anti-inflammatory and pro-apoptotic functions. In keratinocytes, several regulatory miRNAs including miR-1297 and miR-30a showed reciprocal expression changes consistent with anti-inflammatory activity.
Clinical Implications of Mechanistic Findings
Therapeutic Efficacy Mechanisms
The multi-faceted mechanisms of adalimumab contribute to its therapeutic efficacy through complementary pathways. Steric blocking of TNF-alpha prevents receptor interaction, while cytotoxic effects eliminate pathogenic cell populations.
Biomarker Potential
Several mechanistic findings suggest potential biomarkers for treatment monitoring. NF-κB-associated miRNAs emerge as candidates for monitoring therapeutic response.
Resistance Mechanisms
The presence of anti-adalimumab antibodies represents a critical resistance mechanism.
Conclusion
Our findings suggest that adalimumab treatment can return iTNF-alpha levels to those of healthy donors.
References
- Shi Hu et al. (2013). Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular View. Journal of Biological Chemistry
- Carlos Zamora-Atenza et al. (2014). Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis. Arthritis Research & Therapy
- Raghav Oberoi et al. (2016). Targeting Tumor Necrosis Factor-α with Adalimumab: Effects on Endothelial Activation and Monocyte Adhesion. PLoS ONE
- H. Mitoma et al. (2008). Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis & Rheumatism
- J. Boyer et al. (2007). Tumor necrosis factor alpha and adalimumab differentially regulate CD36 expression in human monocytes. Arthritis Research & Therapy
- Shi Hu et al. (2014). Comparison of the inhibition mechanisms of Adalimumab and Infliximab in treating tumor necrosis factor α-associated diseases from a molecular view. Journal of Biological Chemistry
- Chong Shen et al. (2006). Caspase activation and apoptosis induction by adalimumab: Demonstration in vitro and in vivo in a chimeric mouse model. Inflammatory Bowel Diseases
- B. Harvey, Z. Kaymakcalan. (2014). SAT0550 Inhibition of Tnf-Enhanced Human Osteoclast Function by Adalimumab is Influenced by Complex Formation in the Absence of FC Receptor Binding. Annals of the Rheumatic Diseases
- F. Prattichizzo et al. (2016). Anti-TNF-α treatment modulates SASP and SASP-related microRNAs in endothelial cells and in circulating angiogenic cells. OncoTarget
- Aleksandra Plata-Babula et al. (2025). Modulation of Nuclear Factor Kappa B Signaling and microRNA Profiles by Adalimumab in LPS-Stimulated Keratinocytes. International Journal of Molecular Sciences